{"protocolSection":{"identificationModule":{"nctId":"NCT05551182","orgStudyIdInfo":{"id":"NIDY-2022"},"organization":{"fullName":"Phramongkutklao College of Medicine and Hospital","class":"OTHER"},"briefTitle":"Nicergoline Use in Dysphagia Patients","officialTitle":"The Study of Efficacy on Low Dose Nicergoline in Dysphagia Patients Compares With High Dose Nicergoline."},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-09-19","studyFirstSubmitQcDate":"2022-09-19","studyFirstPostDateStruct":{"date":"2022-09-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-21","lastUpdatePostDateStruct":{"date":"2022-12-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Phramongkutklao College of Medicine and Hospital","class":"OTHER"},"collaborators":[{"name":"Silpakorn University","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Dysphagia is a complication in patient with stroke, Parkinson's disease or dementia that can lead to aspiration pneumonia. This study aimed to investigate dysphagia improvement after treatment with nicergoline low dose and high dose, the relationship between nicergoline dose and clinical improvements, side effect of nicergoline and simulation optimal nicergoline dose in dysphagia improvement."},"conditionsModule":{"conditions":["Dysphagia"],"keywords":["Dysphagia","Stroke","Parkinson's disease","Dementia","Dysphagia improvement","Nicergoline"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Nicergoline low dose","type":"EXPERIMENTAL","description":"Nicergoline 10 mg bid (20 mg/day)","interventionNames":["Drug: Nicergoline"]},{"label":"Nicergoline high dose","type":"EXPERIMENTAL","description":"Nicergoline 30 mg bid (60 mg/day)","interventionNames":["Drug: Nicergoline"]}],"interventions":[{"type":"DRUG","name":"Nicergoline","description":"The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.","armGroupLabels":["Nicergoline high dose","Nicergoline low dose"],"otherNames":["Sermion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Rate of dysphagia improvement in low dose nicergoline compare with high dose nicergoline group.","description":"Dysphagia improvement evaluated by physician with GUSS method after nicergoline administration in 4 and 12 week.","timeFrame":"4 and 12 weeks"},{"measure":"Rate of dysphagia improvement in low dose nicergoline and high dose nicergoline group compare pre and post nicergoline treatment each group.","description":"Dysphagia improvement evaluated by physician with GUSS method after nicergoline administration in 4 and 12 week.","timeFrame":"4 and 12 weeks"},{"measure":"Relation between MDL level, substanceP and dysphagia improvement after nicergoline administration both groups (low dose and high dose) in steady state.","description":"Blood sampling for MDL level in Ctrough, Cpeak and substanceP at steady state of nicergoline effect.","timeFrame":"4 weeks"}],"secondaryOutcomes":[{"measure":"Optimal nicergoline dose for dysphagia improvement.","description":"Simulated optimal nicergoline dose by Monte Carlo method with Ctrough, Cpeak and dysphagia improvement","timeFrame":"12 weeks"},{"measure":"Incidence of aspiration pneumonia in low dose nicergoline compare with high dose nicergoline group.","description":"Evaluated by clinical reported from patients and hospitalization data.","timeFrame":"12 weeks"},{"measure":"Rate of cognitive function improvement in low dose nicergoline compare with high dose nicergoline group.","description":"Evaluated by physician with MMSE-Thai 2002 after nicergoline administration in 12 weeks.","timeFrame":"12 weeks"},{"measure":"Rate of cognitive function improvement in low dose nicergoline and high dose nicergoline group compare pre and post nicergoline treatment each group.","description":"Evaluated by physician with MMSE-Thai 2002 after nicergoline administration in 12 weeks.","timeFrame":"12 weeks"},{"measure":"Adverse side effect in low dose and high dose nicergoline treatment.","description":"Blood sampling for renal function (including creatinine serum, creatinine clearance) and uric serum. Other adverse side effect reported by patients/care givers.","timeFrame":"4 and 12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age greater than or equal to 20 years\n* Stroke (post events at least 2 months), Parkinson's disease and dementia patients who have dysphagia symptom\n* Do not take nicergoline prior recruit 2 weeks\n* Continue current medications\n* Consent to join\n\nExclusion Criteria:\n\n* Allergy to gentamicin or components\n* On anticoagulants including Heparin, Enoxaparin, Fondaparinux, Warfarin, Dabigatran, Apixaban, Rivaroxaban and Edoxaban\n* On antiplatelet \\> 1 drug (ex. dual antiplatelet)\n* On ACE-I or Dopaminergic agent 2 months or less\n* Chronic dyspepsia\n* Chronic gout or hyperuricemia \\> 8 mg/dL\n* CrCl \\< 30 ml/min\n* Impair hepatic function including child puge B, C or active hepatitis\n* Brainstem stroke\n* Parkinson plus syndrome: PSP, MSA, DLB, etc\n* Advanced cancer or other medical conditions\n* Bed ridden\n* Laryngopharynx surgery\n* SBP\\<100 or DBP 60 mmHg\n* HR\\<50/min\n* Active bleeding\n* Pregnancy or lactation\n* Known of poor compliance for any treatments","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Jutikan Imsub, PharmD","role":"CONTACT","phone":"0916976705","email":"goku2744@gmail.com"},{"name":"Pasiri Sithinamsuwan, MD","role":"CONTACT","phone":"0832367772","email":"pasiripmk@gmail.com"}],"overallOfficials":[{"name":"Jutikan Imsub, PharmD","affiliation":"College of Pharmacy, Burapha university","role":"STUDY_CHAIR"},{"name":"Sittichoke Sirimontakan, MD","affiliation":"Phramongkutklao hospital and College of Medicine","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Juthathip Suphanklang, BCP","affiliation":"Phramongkutklao hospital and College of Medicine","role":"STUDY_DIRECTOR"},{"name":"Pasiri Sithinamsuwan, MD","affiliation":"Phramongkutklao hospital and College of Medicine","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Phramongkutklao Hospital","city":"Ratchathewi","state":"Bangkok","zip":"10400","country":"Thailand","contacts":[{"name":"Jutikan Imsub, PharmD","role":"CONTACT","phone":"0916976705","email":"goku2744@gmail.com"},{"name":"Pasiri Sithinamsuwan, MD","role":"CONTACT","phone":"0832367772","email":"pasiripmk@gmail.com"},{"name":"Jutikan Imsub, PharmD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Sittichoke Sirimontakan, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Pasiri Sithinamsuwan, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Juthathip Suphanklang, BCP","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":13.759,"lon":100.53358}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000003680","term":"Deglutition Disorders"}],"ancestors":[{"id":"D000004935","term":"Esophageal Diseases"},{"id":"D000005767","term":"Gastrointestinal Diseases"},{"id":"D000004066","term":"Digestive System Diseases"},{"id":"D000010608","term":"Pharyngeal Diseases"},{"id":"D000010038","term":"Otorhinolaryngologic Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M12903","name":"Parkinson Disease","relevance":"LOW"},{"id":"M6594","name":"Dementia","relevance":"LOW"},{"id":"M6572","name":"Deglutition Disorders","asFound":"Dysphagia","relevance":"HIGH"},{"id":"M7775","name":"Esophageal Diseases","relevance":"LOW"},{"id":"M8573","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M6945","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M13205","name":"Pharyngeal Diseases","relevance":"LOW"},{"id":"M12651","name":"Otorhinolaryngologic Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC09","name":"Ear, Nose, and Throat Diseases"},{"abbrev":"BC07","name":"Mouth and Tooth Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000009530","term":"Nicergoline"}],"ancestors":[{"id":"D000000317","term":"Adrenergic alpha-Antagonists"},{"id":"D000018674","term":"Adrenergic Antagonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M12160","name":"Nicergoline","asFound":"MDSC","relevance":"HIGH"},{"id":"M20436","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3359","name":"Adrenergic alpha-Antagonists","relevance":"LOW"},{"id":"M20445","name":"Adrenergic Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}